Qube Research & Technologies LTD Atea Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $60,089 - $73,342	-18,154 Reduced 68.79%	8,235 $27,000
Q1 2024 May 14, 2024	SELL	$3.09 - $4.56 $82,345 - $121,519	-26,649 Reduced 50.25%	26,389 $106,000
Q4 2023 Feb 13, 2024	BUY	$2.8 - $3.35 $37,581 - $44,963	13,422 Added 33.88%	53,038 $161,000
Q3 2023 Nov 13, 2023	BUY	$3.0 - $3.79 $20,487 - $25,881	6,829 Added 20.83%	39,616 $118,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $105,246 - $165,902	32,787 New	32,787 $122,000
Q2 2022 Aug 15, 2022	BUY	$5.33 - $8.18 $111,354 - $170,896	20,892 Added 53.33%	60,067 $426,000
Q1 2022 May 09, 2022	BUY	$5.5 - $9.19 $215,462 - $360,018	39,175 New	39,175 $283,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.